Association between specific enfuvirtide resistance mutations and CD4 cell response during enfuvirtide-based therapy
- 30 November 2007
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 21 (18) , 2537-2539
- https://doi.org/10.1097/qad.0b013e3282f12362
Abstract
Analysis of CD4 cell responses during 48 weeks of enfuvirtide therapy after virological failure (analysis of covariance) demonstrated significant associations between V38 mutations (n = 58 subjects) and continued CD4 cell increases and between Q40 mutations (n = 8) and loss of CD4 cell benefit (+34 versus −95 cells/μl, P < 0.001). Subjects with N43 (n = 20) or other mutations (n = 48) had intermediate CD4 cell responses. These data suggest that key enfuvirtide resistance mutations may be associated with reduced viral pathogenicity in vivo.Keywords
This publication has 15 references indexed in Scilit:
- Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatmentJournal of Antimicrobial Chemotherapy, 2006
- Characterization of Envelope Glycoprotein gp41 Genotype and Phenotypic Susceptibility to Enfuvirtide at Baseline and on Treatment in the Phase III Clinical Trials TORO-1 and TORO-2AIDS Research and Human Retroviruses, 2006
- Long-term monitoring of genotypic and phenotypic resistance to T20 in treated patients infected with HIV-1Journal of Medical Virology, 2005
- Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical TrialsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2005
- Enfuvirtide Resistance Mutations: Impact on Human Immunodeficiency Virus Envelope Function, Entry Inhibitor Sensitivity, and Virus NeutralizationJournal of Virology, 2005
- Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV‐infected patients experiencing prolonged virologic failureJournal of Medical Virology, 2004
- Relative Replicative Fitness of Human Immunodeficiency Virus Type 1 Mutants Resistant to Enfuvirtide (T-20)Journal of Virology, 2004
- Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and AustraliaNew England Journal of Medicine, 2003
- Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South AmericaNew England Journal of Medicine, 2003
- Membrane-Fusing Capacity of the Human Immunodeficiency Virus Envelope Proteins Determines the Efficiency of CD4+T-Cell Depletion in Macaques Infected by a Simian-Human Immunodeficiency VirusJournal of Virology, 2001